Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (9) 2007 NTT JA
|
|
- あゆみ みうら
- 5 years ago
- Views:
Transcription
1 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (9) 2007 NTT JA
2 278 (10) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug (79.0%) Enterococcus faecalis Enterococcus avium Enterococcus spp. Streptococcus anginosus Streptococcus spp. Staphylococcus aureus Staphylococcus spp. Enterococcus spp. Staphylococcus spp. Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa Enterobacter cloacae P. aeruginosa E. cloacae E. coli K. pneumoniae Parvimonas micra Streptococcus constellatus Gemella morbillorum Anaerococcus prevotii Bacteroides fragilis Bilophila wadsworthia Bacteroides thetaiotaomicron Campylobacter gracilis B. thetaiotaomicron B. fragilis Bacteroides caccae B. wadsworthia (MRSA) Enterococcus spp. Teicoplanin MIC 4 mg/ml (MRCNS) 9 MRSA Bacteroides spp. B. wadsworthia Clindamycin (CLDM) Levofloxacin (LVFX) Ciprofloxacin (CPFX) Minocycline (MINO)
3 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (11) I BTB 37 C 1 3 HK BBE PEA HK PV HK 37 C 3 7 MIC2000 II (79.0%) Table (70.6%) (55.3%) (78.6%) (88.2%) (94.0%) 98 (54.1%) 43 (23. 8%) 19 (10.5%) (Fig. 1) % 18.8% % % % % 5
4 280 (12) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 1. Fig % (Fig. 2) (Table 2)
5 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (13) Fig. 2. Table Candida albicans 6 Candida glabrata 3 Candida parapsilosis Candida tropicalis 1 13 C. albicans 7 C. glabrata 3 C. tropicalis 2 C. parapsilosis (Table 3) Streptococcus anginosus Enterococcus faecalis Enterococcus
6 282 (14) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 3.
7 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (15) avium Staphylococcus aureus Enterococcus faecium E. faecalis S. aureus E. faecium Staphylococcus epidermidis E. avium Enterococcus spp. Streptococcus spp. Enterococcus spp. Staphylococcus spp (Table 4) Parvimonas micra Streptococcus constellatus Gemella morbillorum Anaerococcus prevotii (Table 5) Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa Enterobacter cloacae P. aeruginosa E. cloacae E. coli K. pneumoniae (Table 6) Bacteroides fragilis Bilophila wadsworthia Bacteroides thetaiotaomicron Campylobacter gracilis Veillonella spp. B. thetaiotaomicron B. fragilis Bacteroides caccae B. wadsworthia Bacteroides spp Streptococcus spp. Klebsiella spp. Bacteroides spp. Staphylococcus spp. P. aeruginosa (Fig. 3) 3 (Fig. 4) E. coli 2007 B. fragilis 2 (Fig. 5) (Fig. 6) E. faecalis S. aureus % 2005 P. aeruginosa %
8 284 (16) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 4.
9 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (17) Table 5.
10 286 (18) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 6.
11 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (19) Fig. 3. Fig. 4. 1
12 288 (20) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Fig Fig. 6. 1
13 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (21) Fig Fig. 8. MRSA
14 290 (22) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug % E. coli 10% % (Fig. 7) (MRSA) S. aureus MRSA 3 70% (Fig. 8) Bacteroides spp. (18.5%) (23.7%) E. coli (10.1%) Streptococcus spp. (6.3%) Enterococcus spp. (6.2%) 1991 E. coli 1997 (Fig. 9) 6 Enterococcus spp. (20.0%) Bacteroides spp. (13.7%) (11.8%) Staphylococcus spp. (10.4%) (10.1%) Staphylococcus spp. (Fig. 10) E. coli Klebsiella spp Enterococcus spp. E. coli Klebsiella spp % (Fig. 11) Enterococcus spp. (26.8%) Enterobacter spp. (14.6%) Klebsiella spp. (9.8%) P. aeruginosa (9.8%) E. coli (4.9%) 12.2% (Fig. 12) Bacteroides spp % 6 Enterococcus spp. (19.6%) Bacteroides spp. (18.0%) 14.0% Staphylococcus spp. (13.9%) P. aeruginosa (5.0%) (Fig. 13) 5 Table 7 44 MIC 1 Staphylococcus spp. S. aureus 25 Oxacillin (MPIPC) MIC mg/ml 19 (76.0%) 64 mg/ml Ampicillin (ABPC) 4 MIC 2 mg/ml 21 8 mg/ml 128 mg/ml 4 Vancomycin (VCM) Teicoplanin (TEIC) Linezolid (LZD) MIC 2 mg/ml Arbekacin (ABK)
15 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (23) Fig. 9. Fig. 10.
16 292 (24) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Fig. 11. Fig. 12.
17 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (25) Fig. 13. MIC 4 mg/ml Gentamicin (GM) 8 MIC 0.5 mg/ml MIC 32 mg/ml Clindamycin (CLDM) 7 MIC mg/ml 18 MIC 128 mg/ml (Table 7) S. epidermidis 12 MPIPC MIC 16 mg/ml (MRCNS) Minocycline (MINO) MIC 0.5 mg/ml ABK LZD VCM Cefotiam (CTM) Cefozopran (CZOP) TEIC MIC 16 mg/ml TEIC 1 CLDM MIC 0.25 mg/ml mg/ml 5 (Table 8) Staphylococcus spp. 6 Staphylococcus capitis Staphylococcus lugdunensis 2 Staphylococcus haemolyticus Staphylococcus hominis 1 ABK VCM LZD TEIC MINO CZOP (Table 9) S. lugdunensis 2 S. haemolyticus S. hominis S. capitis 1 MPIPC MIC 0.5 mg/ml MRCNS 2 Streptococcus spp. S. anginosus 14 Meropenem (MEPM) Cefpirome (CPR) MIC m g/ml Imipenem (IPM) Cefmenoxime (CMX) CLDM 0.25 mg/ml Ceftazidime (CAZ) Fosfomycin (FOM) (Table 10) Streptococcus spp. 15 Streptococcus oralis 6 Streptococcus salivarius
18 294 (26) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 7. Staphylococcus aureus 25
19 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (27) Table 8. Staphylococcus epidermidis 12
20 296 (28) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 9. Staphylococcus spp. 6
21 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (29) Table 10. Streptococcus anginosus 14
22 298 (30) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 11. Streptococcus spp. 15
23 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (31) Table 12. Enterococcus faecalis 41
24 300 (32) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 13. Enterococcus faecium 22
25 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (33) Table 14. Enterococcus avium 17
26 302 (34) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 15. Enterococcus spp. 14
27 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (35) Table 16. Corynebacterium spp. 11
28 304 (36) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 17. Escherichia coli 43
29 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (37) Table 18. Klebsiella pneumoniae 18
30 306 (38) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 19. Klebsiella oxytoca 8
31 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (39) Table 20. Enterobacter cloacae 16
32 308 (40) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 21. Citrobacter spp. 7
33 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (41) Table 22. Pseudomonas aeruginosa 21
34 310 (42) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 23. Haemophilus spp. 5
35 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (43) Table 24. Streptococcus constellatus 11
36 312 (44) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 25. Streptococcus intermedius 6
37 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (45) Table 26. Gemella morbillorum 7
38 314 (46) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 27. Peptostreptococcus spp. 5
39 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (47) Table 28. Finegoldia magna 6
40 316 (48) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 29. Anaerococcus prevotii 9
41 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (49) Table 30. Parvimonas micra 17
42 318 (50) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 31. Veillonella spp. 14
43 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (51) Table 32. Eggerthella lenta 9
44 320 (52) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 33. Lactobacillus spp. 15
45 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (53) Table 34. Eubacterium limosum 5
46 322 (54) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 35. Actinomyces spp. 6
47 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (55) Table 36. Propionibacterium acnes 8
48 324 (56) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 37. Clostridium spp. 14
49 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (57) Table 38. Bacteroides fragilis 28
50 326 (58) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 39. B. fragilis Bacteroides spp. 80
51 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (59) Table 40. Bilophila wadsworthia 25
52 328 (60) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 41. Campylobacter gracilis 12
53 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (61) Table 42. Fusobacterium spp. 15
54 330 (62) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Table 43. Prevotella spp. 34
55 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (63) Table 44. Porphyromonas asaccharolytica 5
56 332 (64) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Streptococcus parasanguinis 2 Streptococcus bovis Streptococcus agalactiae Streptococcus sanguis Streptococcus equisimilis Streptococcus infantis 1 CLDM MIC mg/ml IPM MEPM TEIC 0.25 mg/ml (Table 11) 3 Enterococcus spp. E. faecalis 41 TEIC MIC 1 mg/ml LZD ABPC VCM IPM MINO (Table 12) E. faecium 22 TEIC MIC 1 mg/ml VCM LZD MIC 2 mg/ml MINO (Table 13) E. avium 17 TEIC MIC 1 mg/ml VCM LZD Levofloxacin (LVFX) Ciprofloxacin (CPFX) MINO (Table 14) Enterococcus spp. 14 Enterococcus gallinarum 4 Enterococcus raffinosus 3 Enterococcus hirae 2 Enterococcus durans Enterococcus casseliflavus Enterococcus pseudoavium 1 Enterococcus spp. 2 TEIC LZD VCM LVFX CPFX MINO (Table 15) 4 Corynebacterium spp. Corynebacterium spp. 11 Corynebacterium striatum 7 Corynebacterium minutissimum Corynebacterium pseudodiphtheriticum 1 Corynebacterium spp. 2 LZD TEIC VCM MINO (Table 16) 5 Escherichia coli E. coli 43 MIC 90 MEPM MIC mg/ml Cefepime (CFPM) CPR CZOP 0.25 mg/ml Carumonam (CRMN) Flomoxef (FMOX) IPM CMX ABPC MIC 90 >128 m g/ml Cefazolin (CEZ) 64 m g/ml CPFX GM 32 m g/ml LVFX 16 m g/ml CTM CMX CPR CFPM CZOP MIC 128 mg/ml 2 (4.7%) 2 extended-spectrum b-lactamase (ESBLs) (Table 17) 6 Klebsiella spp. K. pneumoniae 18 ABPC FOM (Table 18) Klebsiella oxytoca 8 K. pneumoniae (Table 19) 7 Enterobacter cloacae E. cloacae 16 FMOX FOM MIC 90 CPFX LVFX mg/ml MEPM CFPM GM IPM CPR CZOP Amikacin (AMK) (Table 20)
57 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (65) 8 Citrobacter spp. Citrobacter spp. 7 Citrobacter freundii 4 Citrobacter koseri 2 Citrobacter braakii 1 MEPM CPFX LVFX CFPM GM IPM (Table 21) 9 Pseudomonas aeruginosa P. aeruginosa 21 MIC 90 CPFX LVFX 2 mg/ml MEPM GM 4 mg/ml (Table 22) IPM MIC16 mg/ml 3 AMK MIC 32 mg/ml 1 CPFX MIC 4 mg/ml Haemophilus spp. Haemophilus spp 5 MEPM LVFX FOM CPFX CMX MINO (Table 23) 11 Streptococcus constellatus S. constellatus 11 CMX CPR MEPM TEIC Tazobactam/Piperacillin (TAZ/PIPC) (Table 24) 12 Streptococcus intermedius S. intermedius 6 FOM (Table 25) 13 Gemella morbillorum G. morbillorum 7 FOM CAZ (Table 26) 14 Peptostreptococcus spp. Peptostreptococcus spp. 5 TEIC CLDM MINO VCM LZD (Table 27) 15 Finegoldia magna F. magna 6 MEPM TAZ/PIPC IPM TEIC MINO ABPC FMOX (Table 28) 16 Anaerococcus prevotii A. prevotii 9 FOM TEIC CLDM MEPM LZD VCM (Table 29) 17 Parvimonas micra P. micra 17 FOM CLDM (Table 30) 18 Veillonella spp. Veillonella spp 14 TEIC VCM CLDM MIC mg/ml (Table 31) 19 Eggerthella lenta E. lenta 9 TEIC MEPM LZD VCM ABPC (Table 32) 20 Lactobacillus spp. Lactobacillus spp 15 MIC 90 CLDM ABPC 2 mg/ml TAZ/PIPC LZD (Table 33)
58 334 (66) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug Eubacterium limosum E. limosum 5 MEPM TAZ/PIPC CMX CPR CFPM CZOP ABPC (Table 34) 22 Actinomyces spp. Actinomyces spp. 6 CMX IPM FMOX ABPC MINO MEPM (Table 35) 23 Propionibacterium acnes P. acnes 8 CLDM MINO IPM FMOX MEPM TAZ/PIPC (Table 36) 24 Clostridium spp. Clostridium spp. 14 Clostridium perfringens Clostridium ramosum Clostridium tertium Clostridium bifermentans 2 Clostridium cadaveris Clostridium difficile Clostridium hastiforme Clostridium innocuum Clostridium symbiosum Clostridium sp. 1 TEIC MIC 0.5 mg/ml ABPC 2 mg/ml TAZ/PIPC MEPM CLDM FOM (Table 37) 25 Bacteroides spp. B. fragilis 28 MIC 90 TAZ/PIPC IPM 1 mg/ml 2 mg/ml MEPM 4 mg/ml Sulbactam/Cefoperazone (SBT/CPZ) 8 mg/ml MINO (Table 38) CPR CFPM CZOP CLDM B. fragilis Bacteroides spp. 80 B. thetaiotaomicron 27 B. caccae 16 Bacteroides uniformis 12 Bacteroides ovatus Bacteroides distasonis 7 Bacteroides spp. 11 MIC 90 IPM 2 mg/ml MEPM MINO 4 mg/ml SBT/CPZ TAZ/PIPC 16 mg/ml (Table 39) 26 Bilophila wadsworthia B. wadsworthia 25 CLDM MIC 1 mg/ml CPFX LVFX MINO (Table 40) 27 Campylobacter gracilis C. gracilis 12 MIC 90 CLDM 0.5 mg/ml MEPM IPM 2 mg/ml MINO CPFX FMOX 8 mg/ml (Table 41) 28 Fusobacterium spp. Fusobacterium spp. 15 Fusobacterium nucleatum 9 Fusobacterium varium 5 Fusobacterium mortiferum 1 MINO MIC mg/ml MEPM IPM (Table 42) 29 Prevotella spp. Prevotella spp. 34 Prevotella buccae 7 Prevotella melaninogenica 6 Prevotella intermedia 6 Prevotella denticola 5 Prevotella spp. 10 MIC 90 MEPM IPM TAZ/PIPC MINO LVFX
59 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (67) (Table 43) 30 Porphyromonas asaccharolytica P. asaccharolytica 5 (Table 44) III. 16S rrna DNA 31, 32) phylotype phylotype 33, 34) Domain Bacteria Domain Archaea Euryarchaeota Methanobrevibacteria M. smirhii M. oralis 35) B. wadsworthia b- S. aureus MRSA 4 70% LZD MRSA MRSA S. aureus ABK VCM TEIC LZD VCM MIC 2 mg/ml VCM 36, 37) VCM MIC 2 mg/ml (13.3%) (16.1%) 25 1 (4.0%) S. epidermidis (12 ) MPIPC MIC 16 mg/ml MRCNS VCM ABK LZD MIC 2 mg/ml TEIC 8 (66.7%) MIC 4 mg/ml 1 MIC 16 mg/ml CNS 6 3 MRCNS 1 TEIC MIC 8 mg/ml E. coli 1990 Cefazolin (CEZ) 100 mg/ml MIC
60 336 (68) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug % 11,13~15) 2002 MIC 128 mg/ml 3 (10%) 26) CEZ MIC 32 mg/ml 6 (14.0%) CTM CMX CPR CFPM CZOP MIC 128 mg/ml 2 (4.7%) ESBLs TAZ/ PIPC SBT/CPZ MIC 16 mg/ml b- P. aeruginosa IPM 50 mg/ml MIC 20% 24 26) 2005 IPM MIC 16 mg/ml CPFX MIC 4 mg/ml AMK MIC 32 mg/ml CPFX MIC 4 mg/ml 2 AMK MIC 64 mg/ml 1 IPM AMK CPFX 3 A. prevotii E. lenta B. fragilis Bacteroides spp. B. wadsworthia C. gracilis Prevotella spp. CLDM CLDM 2 (229 ) 14 (6.1%) Clostridium spp. CLDM CPFX LVFX 38) 25 (10.9%) B. wadsworthia CLDM b- 39) 40) S. aureus E. coli Klebsiella spp. Enterobacter spp. P. aeruginosa Bacteroides spp. Enterococcus spp. (VRE) (VRSA) ESBLs E. coli P. aeruginosa Bacteroides spp. B. wadsworthia Prevotella spp. b- 1) 1 Jpn. J. Antibiotics 39: , ) 2 Jpn. J. Antibiotics 41: , )
61 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (69) 37: , ) (MRSA) 2: , ) 3: , ) 4: 43 49, ) MRSA 5: , ) Jpn. J. Antibiotics 47: , ) Jpn. J. Antibiotics 47: , ) 24: 40 45, ) Escherichia coli Jpn. J. Antibiotics 49: , ) Pseudomonas aeruginosa Jpn. J. Antibiotics 49: , ) 1994 Jpn. J. Antibiotics 49: , ) 1995 Jpn. J. Antibiotics 50: , ) 1996 Jpn. J. Antibiotics 52: , ) Bacteroides fragilis group 28: 48 54, ) 29: , ) 30: 36 43, ) 30: , ) 1997 Jpn. J. Antibiotics 53: , ) 1998 Jpn. J. Antibiotics 54: , ) 32: , ) 1999 Jpn. J. Antibiotics 55: , ) 2000 Jpn. J. Antibiotics 55: , ) 2001 Jpn. J. Antibiotics 56: , ) 2002 Jpn. J. Antibiotics 57: 33 69, ) 2003 Jpn. J. Antibiotics 58: , 2005
62 338 (70) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug ) 2004 Jpn. J. Antibiotics 59: , ) 2005 Jpn. J. Antibiotics 60: 52 97, ) 2006 Jpn. J. Antibiotics 61: , ) HANDELSMAN, J.: Metagenomics: application of genomics to uncultured microorganisms. Microbiol. Mol. Biol. Rev. 68: , ) HUGENHOLTZ, P.: B. M. GOEBEL & N. R. PACE: Impact of culture-independent studies on the emerging phylogenetic view of bacterial diversity. Bacteriol. 180: , ) HEBB, J. K.: C. R. COHEN & S. G. ASTETE, et al.: Detection of novel organisms associated with salpingitis, by use of 16S rdna polymerase chain reaction. J. Infect. Dis. 190: , ) SIQUEIRA, J. F.: I. N. ROCAS & C. D. CUHA, et al.: Novel bacterial phylotypes in endodontic infections. J. Dent. Res. 84: , ) ROBICHAUX, M.: M. HOWELL & R. BOOPATHY: Methanogenic activity in human periodontal pocket. Curr. Microbiol. 46: 53 58, ) SAKOULAS, G.: P. A. MOISE-BRODER, J. SCHEN- TAG, et al.: Relationship of MIC and bacterial activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42: , ) HIDAYAT, L. K.: D. I. HSU, R. QUIST, et al.: High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166: , ) Clostridium spp. Jpn. J. Antibiotics 60: , ) Bilophila wadsworthia Jpn. J. Antibiotics 59: , ) Jpn. J. Antibiotics 60: , 2007
63 Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (71) Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents Special references to bacteria isolated between April 2007 and March 2008 NAGAO SHINAGAWA and MASAMITSU HASEGAWA Department of Surgery, NTT West Tokai Hospital KOICHI HIRATA, TADASHI KATSURAMAKI and TOHRU MIZUKUCHI First Department of Surgery, Sapporo Medical University, School of Medicine YASUHIDE USHIJIMA and TOMOHIRO USHIDA Department of Surgery, National Hospital Organization, Saitama National Hospital NAOKI AIKAWA and KIKUO YO Department of Emergency and Critical Care Medicine, School of Medicine, Keio University JIRO YURA Digestive Disease Center, Matsunami General Hospital HIROMITSU TAKEYAMA and TAKEHIRO WAKASUGI Nagoya City University Graduate School of Medical Sciences, Department of Gastroenterological Surgery MASAAKI TANIGUCHI Department of Surgery, Ookuma Hospital ISAMU MIZUNO Department of Surgery, Nagoya Midori Municipal Hospital KEIJI MASHITA Department of Surgery, Bisai Hospital SYU ISHIKAWA Department of Surgery, Takahama Municipal Hospital AKIRA MIZUNO Department of Surgery, Inabe General Hospital NORIAKI MOORI NAOKI SUMITA Department of Surgery, Chita Kosei Hospital SHOJI KUBO and SHIGERU LEE Department of Gastroenterological and Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine TORU OOMURA Department of Surgery, Fujiidera City Hospital YASUHITO KOBAYASHI and TAKESHI TSUJI Department of Surgery, Wakayama Rosai Hospital HIROKI YAMAUE and MANABU KAWAI Second Department of Surgery, Wakayama Medical School YOSHIO TAKESUE Department of Infection Control, Hyogo Medical School NORIAKI TANAKA Department of Gastroenterological Surgery, Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences HIDEYUKI KIMURA Department of Surgery, Okayama Saiseikai Hospital HIROMI IWAGAKI Department of Surgery, National Hospital Organization, Fukuyama National Hospital TAIJIRO SUEDA, EISO HIYAMA, YOSHIAKI MURAKAMI, HIROKI OOGE and KENICHIRO UEMURA Department of Surgery, Graduate School of Biomedical Sciences, Hiroshima University
64 340 (72) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug HIROAKI TSUMURA Department of Surgery, Hiroshima City Funairi Hospital TAKASHI YOKOYAMA Aki City Hospital HITOSHI TAKEUCHI and YOSHIMASA YASUI Department of Surgery, National Hospital Organization, Iwakuni National Hospital YOICHI YASUNAMI and SHINICHIRO RYU Department of Surgery 1, Fukuoka University, School of Medicine Bacteria isolated from infections in abdominal surgery during the period from April 2007 to March 2008 were investigated in a multicenter study in Japan, and the following results were obtained. In this series, 707 strains including 24 strains of Candida spp. were isolated from 181 (79.0%) of 229 patients with surgical infections. Three hundred and ninety-five strains were isolated from primary infections, and 288 strains were isolated from postoperative infections. From primary infections, anaerobic Gram-negative bacteria were predominant, followed by aerobic Gram-negative bacteria, while from postoperative infections aerobic Gram-positive bacteria were predominant, followed by anaerobic Gramnegative bacteria. Among aerobic Gram-positive bacteria, the isolation rate of Enterococcus spp. was highest, followed by Streptococcus spp., and Staphylococcus spp. in this order, from primary infections, while Enterococcus spp. was highest, followed by Staphylococcus spp. from postoperative infections. Among aerobic Gram-negative bacteria, Escherichia coli was the most predominantly isolated from primary infections, followed by Klebsiella pneumoniae, Pseudomonas aeruginosa and Enterobacter cloacae, in this order, and from postoperative infections, P. aeruginosa was most predominantly isolated, followed by E. cloacae, E. coli and K. pneumoniae. Among anaerobic Gram-positive bacteria, the isolation rate of Parvimonas micra was the highest from primary infections, followed by Streptococcus constellatus and Gemella morbillorum, and from postoperative infections, Anaerococcus prevotii was most predominantly isolated. Among anaerobic Gram-negative bacteria, the isolation rate of both Bacteroides fragilis and Bilophila wadsworthia were the highest from primary infections, followed by Bacteroides thetaiotaomicron and Campylobacter gracilis, and from postoperative infections, B. thetaiotaomicron was most predominately isolated, followed by B. fragilis, Bacteroides caccae and B. wadsworthia in this order. In this series, we noticed no vancomycin-resistant Gram-positive cocci, nor multidrugresistant P. aeruginosa. There were nine strains of coagulase-negative Staphylococci which show higher MIC against teicoplanin more than 4 mg/ml, but all of them had good susceptibilities against various anti-mrsa antibiotics. We should carefully follow up B. wadsworthia which was resistant to various antibiotics, and also Bacteroides spp. which was resistant to many b-lactam antibiotics.
02-(a)-Łi’ì™·Łv-4.11
THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 105( 13 ) 2001 1) 2) 3) JA 2 7 1) 2) 3) 106( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. 1982 7 2001 (2001.4 2002.3) 1 221 175 (79.2%) 420 186 234 Staphylococcus
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 33( 33 ) 2002 JA * 1 * 2 2003 12 15 * 1) * 2) 34( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1982 7 2002 (2002.4 2003.3) 1 174 131 (75.3%) 334 171 163 Staphylococcus
More informationApr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 13 ) 2008 NTT
Apr. 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 12 105 ( 13 ) 2008 NTT 106 ( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr. 2010 JA 2010 1 27 1982 7 2008 2008 4 2009 3 1 215 173 (80.5%) 694 18 357
More informationStreptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus
More information日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
More information03-b-„FŒ{›xŒ¾-4.02
518( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 1. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 519( 31 ) 9 5 2003 8 2004 7 14 565 701 258 (36.8%) 443 (63.2%) Staphylococcus aureus
More information日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
More informationCHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
More informationR06_01
Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2
More informationStaphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis
Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)
More informationuntitled
111-245010-N-04 21300AMY00327000 20116 2 20099 1 BD BBLCRYSTAL ANR BD BBLCRYSTAL ANR 4-A 2-A 1-A 4-B 2-B 1-B 4-C 2-C 1-C 4-D 2-D 1-D 4-E 2-E 1-E 4-F 2-F 1-F 4-G 2-G 1-G 4-H 2-H 1-H 4-I 2-I 1-I 4-J 2-J
More informationDec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) ) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 1
Dec. 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 46 431 ( 45 ) 2006 1) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 16) 16) 17) 17) 1) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10)
More informationCHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
More information2.7 臨床概要
2.7 臨床概要 A/G Al-P ALT AST AT- AUC AZM BIPM BP BUN CEZ CFPN-PI CFU CLcr Cmax CNS COPD CPFX CRP CS CYP CVA DBT DHP-I DIC DRPM DRPM-DC FAS γ-gtp GCP GNB GNF-GNR GPB HAM - Staphylococcus C P450 -I Full Analysis
More informationCHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
More informationepidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
More informationR01
1. 集計対象医療機関数 (1,792 医療機関 ) 13.2% (7 医療機関 ) 900 床以上 N=53 86.8% (46 医療機関 ) 19.2% (70 医療機関 ) 500 899 床 N=365 80.8% (295 医療機関 ) JANIS 参加 * 200 499 床 N=2,231 43.4% (968 医療機関 ) 56.6% (1,263 医療機関 ) JANIS 参加 200
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium
More information70( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Meropenem 2002 * * * * * * * * * * * * * * * * * * * * * * NTT Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 71( 71 ) * * * * 2003 12 22 Meropenem
More information日本化学療法学会雑誌第53巻第S-3号
moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium
More information1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus
More informationVOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
More information日本化学療法学会雑誌第51巻第4号
000 000 0 000 0 Methicillin resistant Staphylococcus aureusmrsa.methicillin resistant S. epidermidismrse.0 MRSA MRSE arbekacinabkquinupristindalfopristinqprdpr vancomycin MIC0. ml Streptococcus pneumoniae
More informationCHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
More informationFig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
More informationCHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
More informationuntitled
Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium
More informationDIC vegetation 1 nonbacterial thrombogenic e
2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus
More informationVOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
More informationTable 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
More informationStaphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
More informationCHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc
APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus
More information2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 1 1 2013 69 11,762 2015 11 16 1994 2013 69 19 11,762 FQ 33 Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae
More informationPCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin
Key words : Clinical isolates, Antibacterial susceptibility, Scale of hospital PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC=
More informationClostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
More informationVOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
More information1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
More informationVOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia
ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas
More information04-c-„FŒ{›xŒ¾-4.01
544( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 2. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 545( 57 ) 9 5 2003 8 2004 714 565 719 50 20 39 0 9 70 79 44.4 91.7% Escherichia coli
More informationTable 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
More informationVOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
More informationCHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
More informationTable 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
More informationFeb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 11( 11 ) 2003 12 17 (MRSA) penicillin-resistant Streptococcus pneumoniae (PRSP) 3 I. 12( 12 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 3 1997 1) (1985)
More informationCHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
More informationCHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
More informationTable 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
More information公開情報 2016 年 1 月 ~12 月年報 ( 全集計対象医療機関 ) 院内感染対策サーベイランス検査部門 Citrobacter koseri Proteus mirabilis Proteus vulgaris Serratia marcescens Pseudomonas aerugino
公開情報 2016 年 1 月 ~12 月年報 ( 全集計対象医療機関 ) 院内感染対策サーベイランス検査部門 検査部門におけるサーベイランスの概要と目的 本サーベイランスの目的は 細菌検査により検出される主要な細菌の分離頻度とその抗菌薬感受性を継続的に収集 解析し 医療機関における主要な細菌ならびに薬剤耐性菌の分離状況を明らかにすることである サーベイランスの対象となる主要菌ならびに薬剤耐性菌の分離率は
More informationTable 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
More information概要 (2004 年分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 ( ) 内は施設数 2002 年 2003 年 2004
More informationCHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
More informationCHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str
cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
More informationOct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz
Oct. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 5 327 27 2013 2014 2016 7 5 2013 2014 Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, tazobactam/piperacillin TAZ/PIPC, ceftazidime CAZ, cefepime
More information(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia
Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor
More information概要 (2006 年 1 2 3 月分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動 向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 2005 年 2006 年 10~12
More informationTable 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
More informationTable 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
More information366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
More informationCHEMO THE RAPY OCT. 1994
bilis (0.78), Proteus vulgaris (1.56), Enterococcus faecalis (3.13), Staphylococcus epidermidis (6.25), Klebsiella pneumoniae (6.25), Morganella morganii (6.25), Escherichia coli (12.5), Providencia rettgeri
More informationVOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
More information400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
More informationKey words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
More information日本化学療法学会雑誌第65巻第3号
μ Key words Chlamydia trachomatis C. trachomatis I Table1.Observation items, categories and scores Observation item Category Score Body temperature () Lower abdominal pain Uterine corpus tenderness Condition
More informationVOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae methicillin-resistant Staphylococcus
More informationFig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
More informationTable 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det
Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not detected *: time after last administration Table 2. Concentration
More informationCHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
More informationFig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
More informationスライド タイトルなし
第 4 回ひびき臨床微生物シンポジュウム June 24,27, 港ハウス 感受性検査を読む ( 同定検査結果確認やスクリーニング検査と捉えて ) ( 株 ) キューリン小林とも子 キューリン微生物検査課 塗抹鏡検グラム染色 分離培養検査血液 BTB, エッグーヨーク 報告書作成結果承認 同定検査 VITEK TSI,LIM クリスタル NF 薬剤感受性検査 MIC2 ディスク法 薬剤感受性結果 (
More information) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky
2.7 2.7.5 1) 199846410-437 2) UTI ( )UTI ( 3 )Chemotherapy (Tokyo) 1986 34408-441 3) () 199745762-778 4) 1992 5) 199543 6) Chemotherapy (Tokyo) 199139687-689 7) Imipenem/Cilastatin sodium (MK-0787/MK-0791)
More informationCHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),
More informationVOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
More information第65回日本化学療法学会東日本支部総会 抄録
鍵 76 Clostridioides difficile C. difficile 77 γ γ Mycobacterium avium 78 79 Clostridium difficile Treponema pallidum 80 81 82 in vitro in vitro 83 鍵 Treponema pallidum 84 Chlamydia trachomatis Mycoplasma
More informationGenus Corynebacteria Non-lipophilic The nonlipophilic bacteria may be classified as fermentative and non-fermentative: Fermentative Corynebacteria Cor
Corynebacterium kroppenstedtii Genus Corynebacteria Non-lipophilic The nonlipophilic bacteria may be classified as fermentative and non-fermentative: Fermentative Corynebacteria Corynebacterium diphtheriae
More informationCHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
More informationVOL.30 NO.10 CHEMOTHERAPY 1123 Fig,1 Group B case 6 hepatolithiasis,e.k.66 y.0.,f.45kg Postoperative wound infection Fig.2 Group B case 15 gastric cancer,k.k.60 y.o.,m. Postoperative peritonitis Fig.3
More informationMicrosoft PowerPoint .片山(HP用修正).pptx
平成 29 年度 第 1 回三重県感染対策 援ネットワーク研修会 2017/07/09 ( 臨床第 2 講義室 ) 講演 2 アンチバイオグラムの活 アンチバイオグラム作り 使い 独 政法 地域医療機能推進機構 四 市 津医療センター 薬剤科 副薬剤科 歳也 Japan Community Health care Organization (JCHO) Yokkaichi Hazu Medical
More informationTable 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
More informationcoccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof
242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF
More information252166.indd
BBLCRYSTAL for Windows Ver.5.4 NEISSERIA/HAEMOPHILUS CDC BLOOD AGAR CDC BLOOD AGAR ALTERNATE BLOOD AGAR BBL SCHAEDLER BLOOD AGAR 2007/7 ENTERIC/NON FERMENTER 252166 1. 2 2. 3 3. 4 4. 5 5. 7 6. BBL 8 7.
More informationHelicobacter pylori Helicobacter pylori Helkobacter pylori erythromycin (EM) Mueller Hinton broth (Difco) H. pylori Staphylococcus aureus ATCC 29213 Escherichia coli ATCC25922 amoxicillin (AMPC), clarithromycin
More informationTable 1-1. Criteria for evaluation Table 2. Criteria for bacteriological efficacy Table 1-2. Criteria for evaluation Table 3. Reasons for exclusion and drop-out from evaluation (clinical efficacy) Table
More information日本化学療法学会雑誌第53巻第S-1号
Doripenem in vitro Doripenem in vitro 7 7 3 DRPM in vitro DRPM 00 DRPM Staphylococcus Streptococcus µ gml MIC90 Moraxella catarrhalishaemophilus influenzae µ gml MIC90 imipenem IPM panipenem meropenemmepm
More informationMIC MIC...
50 mg 10% 2.7.36 2.7.36 2.7.36... 1 1.6... 1 2.6... 3 3.6... 5 3.16... 5 3.26... 12 3.36... 16 4.6... 17 5.6... 19 6.6... 20 2.7.3.3.16-1 MIC... 9 2.7.3.3.16-2 MIC... 10 2.7.3.3.16-3 MIC E. coli... 11
More informationCHEMOTHERAPY
VOL.40 S-1 coagulase negative Staphylococcus sp, methicillin- resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter
More informationCHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac
CHEMOTHERAPY DEC. 1988 phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepacia 1 Bacteroides bivius Propionibacterium granulosum
More informationTitle 尿路感染症分離菌の年次的変遷と薬剤感受性の検討 ( ニューキノロン系を中心として ) 深津, 英捷 ; 本多, 靖明 ; 水本, 裕之 ; 瀧, 知弘 ; 三井, Author(s) 々村, 仁志 ; 羽田野, 幸夫 ; 平岩, 親輔 ; 吉川, 和宏 ; 山田彰 ; 瀬川, 昭夫 Ci
Title 尿路感染症分離菌の年次的変遷と薬剤感受性の検討 ( ニューキノロン系を中心として ) 深津, 英捷 ; 本多, 靖明 ; 水本, 裕之 ; 瀧, 知弘 ; 三井, Author(s) 々村, 仁志 ; 羽田野, 幸夫 ; 平岩, 親輔 ; 吉川, 和宏 ; 山田彰 ; 瀬川, 昭夫 Citation 泌尿器科紀要 (1992), 38(11): 1215-1223 Issue Date
More information日本化学療法学会雑誌第58巻第4号
Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p
More information988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
More informationCHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);
VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical
More informationKey words: Antibiotics, Intestinal bacterial flora, Germfree mouse
Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse Table 1 Susceptibility to various antibiotics Antibiotics Abbreviations ABPC: GM: CET: CEZ: CMZ: LMOX: CMX: Bacteriae used Ampicillin
More information第82 回日本感染症学会総会学術集会後抄録(II)
Corydoras sterbai Kryptopterus bicirrhis Petitella georgiae Xiphophorus maculatus rpob Xba Mycobacterium szulgai Mycobacterium gordonae M. szulgai M. gordonae M. avium M. szulgai M. gordonae M. szulgai
More informationVOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers
VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers CHEMOTHERAPY MAY 1988 Table 2 Experimental schedule of CS-807 administration and sampling of feces Table 3 Isolation of aerobic and anaerobic
More information東洋医学雑誌
Vol.67 No.2 123-130, 2016 Akiyo GUSHI a Chihaya KORIYAMA b Ryo YOSHINAGA c Hiromi YANO c Junichi TSUMAGARI d Eiichi TAHARA c a Gushi Dermatological Clinic, 45-3 Higashiohsyoji, Satsumasendai city, Kagoshima
More informationKey words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin
More information1BD BBLCRYSTAL RGP Aerococcus viridans Arcanobacterium pyogenes Bacillus cereus Bacillus licheniformis Bacillus megaterium Bacillus pumilus Bacillus s
111-245150-N-03 21400AMY00151000 20099 1 BD BBLCRYSTAL RGP BD BBLCRYSTAL RGP 4-A 2-A 1-A 4-B 2-B 1-B 4-C 2-C 1-C 4-D 2-D 1-D 4-E 2-E 1-E 4-F 2-F 1-F 4-G 2-G 1-G 4-H 2-H 1-H 4-I 2-I 1-I 4-J 2-J 1-J -D-
More informationTable 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
More information